ATSENA THERAPEUTICS GRANTED U.S. FDA FAST TRACK DESIGNATION FOR ATSN-201 GENE THERAPY TO TREAT X-LINKED RETINOSCHISIS

Reuters · 03/12 11:30

Please log in to view news